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Diet plays a crucial role in cancer advancement as 
well as prevention. Breast cancer is the second leading 
cause of cancer death among women. Recent research 
links breast cancer with diet and some evidence for the 
preventive effect of diet against breast cancer was also 
documented. The growth of cancer cells is influenced by 
natural sweetener honey and its multitude of phenolic 
phytochemical components. Honey has been used med-
icinally by ancient Greeks and Egyptians and also tradi-
tionally exploited in Ayurveda and Chinese medicine. In 
this paper, the anti-cancer properties of honey and its 
phytochemical’s action against breast cancer have been 
summarized. They result in apoptosis by enhancing re-
active oxygen species level, activating mitochondrial 
pathway, initiation of pro-apoptotic and anti-apoptotic 
proteins, induction of p53 pathway that finally cause 
DNA fragmentation. However, there is a necessity for 
more proteomic and genetic-based experiments to  
understand its molecular mechanism to promote honey 
and its phenolic markers as plausible candidates for 
breast cancer treatment. Further, there is a need for 
quality check of honey available in the market, which 
warrants significant investigation by researchers in the 
food industry to ensure their attributes. 
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CANCER is not just one disease, but also a large group of  
almost 100 diseases1. In 2014 alone, 585,720 deaths  
occurred due to cancer, corresponding to about 1600 
deaths per day2. Skin, lung, colon, breast and prostate are 
the most frequent type of cancers. Among these, breast can-
cer is found to occur commonly in about 12% of women, 
i.e. 1 in 8 women are found to develop invasive breast can-
cer in the world. According to the American Cancer Soci-
ety, about 231,840 new cases and 40,290 deaths due to 
invasive breast cancer were expected in 2015 in USA3. 
 A major cause for cancer is the variations that occur in 
the DNA sequence of a normal cell. Breast cancer in parti-
cular, develops from a mutated gene4. Mutation is  
defined as a permanent variation in the nucleotide  
sequence of a nucleus of an organism like virus or other 
genetic elements or changes in extrachromosomal DNA. It 
is influenced by exposure to radiation, hazardous chemicals 
or genetically obtained5. Several studies examined the die-
tary–gene relationship between breast cancer cells and natu-
ral food substances. These natural compounds have their 
benefits and some are detrimental to breast cancer cells6. 
 Many studies have promoted the natural food, honey, 
against cancer. Honey is a sweet food created by honey 
bees with the help of nectar collected from various flow-
ers. Honey, consumed by humans for a long time, is used 
as a sweetener and flavouring in various recipes and bev-
erages. It is a mixture of sugars and other phytochemi-
cals7. Honey was used medicinally by ancient Egyptians 
and Greeks. It is also used in Chinese medicine as well as 
in Ayurveda8. It was applied externally to treat wounds 
and burns; and to treat internal ailments like gastric dis-
turbances and ulcers through oral intake by humans. In 
modern times, it is used for treating cough and rhinosi-
nusitis9. Honey is said to have an anti-proliferative effect 
on various cancer cells which involves programmed cell 
death with significant changes in cell organelles. Along 
with honey, other phenolic compounds in honey have 
been examined for their effect on cancer cells10. These 
phytochemicals in honey belong to polyphenol family. 
This article highlights the activities stimulated by honey 
and its polyphenols on various breast cancer cell lines 
leading to cell lysis. Before venturing into this, a brief in-
troduction about the biology of breast cancer is provided. 
Biology of breast cancer 
Breast cancer is a cancer that develops in the breast tis-
sue. Breast cancers are carcinomas that start in epithelial
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Figure 1. Genes related to breast cancer. BRCA1 (breast cancer 1 early onset) and BRCA2 (breast can-
cer 2 early onset) genes; ATM (ataxia telangiectasia mutated), TP53 (tumour protein p53), CHEK2 
(checkpoint kinase 2), PTEN (phosphatase and tensin homolog), CDH1 (Cadherin-1), STK11 (ser-
ine/threonine kinase 11) and PALB2 (Partner and localizer of BRCA2) genes. 
 
 
cells present in the breast due to mutation11. About 10–
15% of breast cancer cases are thought to be hereditary, 
which are genetically inherited from any one of the par-
ents (acquired mutations)12. The most common cause of 
hereditary breast cancer is an inherited mutation in cer-
tain genes which are given in Figure 1. Having children 
after the age of 30, consumption of oral contraceptives, 
hormone therapy after menopause, physical inactivity and 
drinking alcohol are other factors that influence this can-
cer13. Studies have shown that alcohol intake does not in-
fluence breast cancer among BRCA mutation, while 
consumption of wine in BRCA1 mutation carriers have 
relationship with breast cancer14. 
 Breast cancers which contain progesterone receptors 
(PR) are referred as PR-positive (or PR+) cancers, while 
those that have estrogen receptors (ER) are commonly 
called ER-positive (or ER+) cancers and those which 
have growth-promoting protein called HER2/neu (often 
just shortened to HER2) are known as HER2-positive15. 
The available choice of breast cancer treatment includes 
chemotherapy, surgery, radiation therapy, targeted ther-
apy, bone-directed therapy and hormone therapy. Of 
these, chemotherapy (chemo) consists of anti-cancer 
drugs that may be given intravenously or orally in order 
to kill rapidly growing cancer cells. Chemotherapy can be 
employed in case of women whose cancer has spread out-
side breast or after initial treatments16. The most common 
chemo-preventives used for breast cancer are cyclophos-
phamide, methotrexate, 5-fluorouracil and doxorubicin17. 
These chemo-preventives are more potent only at the ear-
ly stages of cancer detection which makes scientists to 
search for a novel drug. In the following section, honey 
and its phenolic components are introduced which serve 
as putative candidates in search of novel drugs for cancer. 
Honey and its phenolic constituents 
Honey remains a natural sweetener for food to humans 
for several centuries. It is a useful food substance which 
is mostly made up of sugar and water along with minute 
quantities of minerals as well as pigments, flavour and 
aroma substances and phenolic compounds18. For this 
reason it is characterized as a supersaturated sugar solu-
tion. Apart from being the only source of sweetener, it 
was also employed in ancient medicine to treat various 
ailments and complaints. It was applied externally in case 
of burns, wounds and acne as well as internally for 
cough, seasonal allergies, to boost immunity, urinary 
tract disorders, diarrhoea, bronchial asthma, nausea, 
etc.8,9. Besides these, scientists have found that honey has 
anti-inflammatory, anti-bacterial, anti-malarial and anti-
cancer properties. Despite the high amount of sugar pre-
sent in it, its biological properties have a strong relation 
to the minute quantity of phenolic compounds. 
 Nevertheless, phenolic content as well constituents pre-
sent in honey differ, depending on its floral or botanical 
origin. There are different methods to find various combi-
nations of phenolic constituents in different honey. Some 
types of honey and their phenolics are given in Table 1. 
The phenolic constituents of eucalyptus honey are chry-
sin, tricetin, luteolin, myricetin quercetin-3-methyl ether,
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Table 1. Type of honey and the identified phenolic compounds 
Type of honey Identified phenolic compounds Reference 
   
Eucalyptus honey Myricetin, tricetin, quercetin, luteolin, quercetin-3-methyl ether, kaempferol, pinocembrin,  
chrysin, pinobanksin, isorhamnetin, genkwanin 
19 
Rosemary honey Kaempferol, ferulic acid, chrysin, pinocembrin, p-coumaric acid 20 
Indian honey Dihydroxy benzoic acid, caffeic acid, ferulic acid and cinnamic acid 21 
Tualang honey Benzoic acid, gallic acid, syringic acid, p-coumaric acid, hyacinthin, trans-cinnamic acid, 
caffeic acid, catechin, kaempferol and naringenin 
22 
Thyme honey Caffeic acid, chlorogenic acid, p-coumaric acid, ferulic acid, gallic acid, gentisic acid,  
sinapic acid, syringic acid 
23 
New Zealand and Australian  
 Leptospermum honey 
Myricetin, tricetin, quercetin, luteolin, kaempferol, kaempferol-8-methyl ether,  
pinocembrin, chrysin, gallic acid, ellagic acid, chlorogenic acid, caffeic acid,  
p-coumaric acid, ferulic acid, syringic acid 
24 
Greek unifloral honey  Syringic acid, myricetin, quercetin, kaempferol and chrysin 25 
 
 
 
 
Figure 2. Phenolic markers of honey and their chemical structures. 
 
 
isorhamnetin, kaempferol, pinocembrin, quercetin, genk-
wanin and pinobanksin19. Rosemary honey contains com-
pounds like chrysin, kaempferol, p-coumaric acid, 
pinocembrin and ferulic acid20. Cinnamic acid, dihydroxy 
benzoic acid, caffeic acid and ferulic acid are the major 
phenolic constituents found in the Indian honey sam-
ples21. The phenolic constituents of tualang honey was 
benzoic acid, catechin, naringeningallic acid, syringic  
acid, p-coumaric acid, hyacinthin, kaempferol, trans-
cinnamic acid and caffeic acid22. Similarly, thyme honey 
contained gallic acid, chlorogenic acid, syringic acid,  
ferulic acid, gentisic acid, caffeic acid, sinapic acid and 
p-coumaric acid23. The phenolic compounds of New Zea-
land and Australian leptospermum honey are: quercetin, 
luteolin, kaempferol, myricetin, kaempferol-8-methyl 
ether, chlorogenic acid, caffeic acid, gallic acid,  
p-coumaric acid, ferulic acid, pinocembrin, chrysin, trice-
tin, ellagic acid and syringic acid24. Phenolic profile of
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Figure 3. Factors influencing the bioavailability of phytochemicals. 
 
 
the Greek unifloral honey was evaluated based on quanti-
fication of syringic acid, myricetin, quercetin, kaempferol 
and chrysin using high performance liquid chromatogra-
phy25. These phenolic compounds are classified as pheno-
lic acids, flavonoids, flavones, flavanones, flavonols, etc. 
This classification is based on the chemical group present 
in them. A schematic representation of the classification 
of phenolics of honey along with their chemical structure 
is given in Figure 2. 
 Similar to phenolic constituents, the phenolic concen-
tration of honey varies depending on the type of flower 
and its origin. For instance, total phenolic amount was 
found to vary between 82.5 and 242.5 mg/kg when 40 
honey samples of different floral types such as multifloral, 
lime, rape, raspberry, mixture and honeydew were  
studied26. While the phenolic content in coconut honey 
was found to be 15.6 g/g, it was 21.4 g/g in Gelam  
honey27. Polyphenolic phytochemicals present in honey 
may be classified as flavonoids and phenolic acids. The 
overall flavonoid content is said to be around 20 and 
2400 g/100 g (ref. 28). The total phenolic content of the 
North-East Nigerian honey was found to be 65.31  
19.50 mg gallic acid equivalent (GAE)/100 g (ref. 29). 
Apart from phenolics, the colour, flavour and taste of  
honey also differ depending on their source. The colour 
of honey usually varies from water white to dark amber 
and has a strong relation to the phenolic content present 
in it. Dark coloured honey is said to have a strong flavour  
and high phenolic content than the mild coloured  
honey types30–32. This was found to be evident in the 
study on 23 types of Saudi Arabia honey33. Regardless of 
all these diverse factors, polyphenols of honey are exten-
sively studied for their biological benefits. However, it  
is essential to understand the bioavailability of honey  
and its components before explaining its anti-cancer  
activity. 
Honey and its bioavailability 
Bioavailability becomes an important factor to be studied 
when the medicinal property of a compound is explored. 
It becomes a foremost factor while deliberating a dietary 
substance for therapy. The bioavailability of honey poly-
phenols in human beings as well as their anti-oxidant  
capacity was experimented using 40 individuals by 
Schramm et al.34. Two different buckwheat honey with 
0.79  0.02 (Low-A) and 1.71  0.21 (High-A) mg of 
phenolic anti-oxidants per gram were used in the study. 
The results showed a rise in antioxidant activity along 
with total-phenolic content and fall in the capacities of 
plasma (P < 0.05) after honey treatment34. This study 
supports the observation that the phenolics of honey are 
not only bioavailable but also exhibit excellent anti-
oxidant activity. 
 Honey is an excellent source of flavonoids and phenolic 
acids. Numerous studies have shown that bioavailability 
of polyphenol is complex influenced by several factors 
(Figure 3). Besides these factors, swift elimination and 
limited absorption of natural polyphenols make the final 
plasma concentrations of flavanones and isoflavones to be 
at around 5 M/l, while that of oligomeric flavonoids to be 
at 1 M/l (refs 35, 36). Hence, phenolic substances can 
be made bioavailable by repeated consumption of food 
substances. 
 Despite these difficulties, there are a few supporting 
factors that make phenolics of honey easily bioavailable. 
It is found that the flavonoids with glycoside form en-
courage the Na+-dependent transport of ATPase of mono-
saccharides in intestinal epithelial cells during studies on 
the bioavailability of natural flavonoids. Natural flavonoids 
are hydrolysed to aglycones which can be easily absorbed 
by enterocytes (intestinal absorptive cells). In case of bee 
honey, enzyme glycosidase present in the bee salivary 
REVIEW ARTICLES 
 
CURRENT SCIENCE, VOL. 112, NO. 9, 10 MAY 2017 1843 
gland makes flavonoids of honey to be present in the  
aglycones form. Aglycones form is created when the gly-
cosyl group of a glycoside is replaced by hydrogen. Phe-
nolic aglycones are highly absorbed through the gut 
barrier in comparison to their corresponding glycosides. 
Therefore, it is assumed that honey flavonoids are effort-
lessly bioavailable than other natural flavonoids37,38. 
 Phenols of honey also exhibit synergestic influence 
along with medicinal benefits. Synergism can be defined 
as the interaction between two or more substances caus-
ing an improved effect compared to the sum of their indi-
vidual effects39. Synergy can be additive or reversal, out 
of which additive occurs when the interaction effect of 
chemicals is enhanced. Phenolic compounds are tested 
for their synergistic property with medically approved 
drugs available in the market against various cancer 
types. These compounds commonly increase the effect of 
anti-cancer drugs when used in combination rather than 
when used alone. In particular, phenolic compounds such 
as chrysin, apigenin, ferulic acid and quercetinare are 
found to show synergistic effect when combined with 
medically approved drugs such as 5-fluorouracil, tamo-
xifen, doxorubicin against different breast cancer cell 
lines40–43. The combination of phenolic phytochemicals 
and anti-cancer drugs subdued breast cancer cell growth 
with greater potential. Especially, the combination of 
phenolic constituents like quercetin and kaempferol is 
found to show excellent synergistic effect against breast 
cancer cell lines44–46. Their combination showed efficient 
suppression of cell proliferation and invasion of cancer 
cells. As these phenolic compounds co-exist in various 
concentrations, their synergistic effect is expected to 
promote honey as a remarkable applicant for breast can-
cer prevention and treatment. In the following section, the 
effect of crude honey against numerous breast cancer cell 
lines in laboratory conditions as well as animal models is 
highlighted before discussing the individual polyphenols 
anti-cancer effect. 
Honey and breast cancer 
Anna et al.47 found that Greek honey had a bioactivity on 
MCF-7 breast cancer cells. The Greek honey had a weak 
osteogenic effect in low concentration against the MCF-7 
cells. The cell viability of MCF-7 cells was reduced after 
treatment with honey. The cell proliferation lessened due 
to honey’s effect on mitochondria, inducing apoptosis47. 
The effect of crude honey samples collected from Egyp-
tian floral sources (Ziziphus spina-Christi, Citrus reticu-
late and Cassia javanica) was determined by in vitro 
study. The anti-cancer as well as antimycotic activity of 
the samples was observed using HTB-26 breast tumour 
cell line. However, crude Ziziphus honey had significant 
effect on cancer cells, compared to the other crude honey 
tested. The concentration of crude Ziziphus played a  
major a role in inhibiting the proliferation48. Jaganathan et 
al.49 performed an in vitro evaluation of anti-oxidant as 
well as cytotoxic properties of Indian honey. The cyto-
toxic activity was tested against MCF-7 breast cancer 
cells. Indian honey retarded the cancer cell growth with 
increase in concentration along with increase in cells at 
the sub-G1 phase, showing the occurrence of apoptosis in 
breast cancer cells49. This was followed by the study of 
effect of honey on ehrlich ascites carcinoma50. Ehrlich 
ascites carcinoma is an impulsive murine mammary  
adenocarcinoma present in the ascites form and usually 
produced in out-bred mice via serial intraperitoneal (i/p) 
passages. The growth of ehrlich ascites carcinoma was 
significantly inhibited up to 39.98% by honey containing 
higher phenolic content of about 25% (volume/volume) 
when intraperitoneally injected. 
 Fauzi et al.51 examined the effect of Tualang honey 
(TH) on two breast cancer cell lines, MCF-7 and MDA-
MB-231. Apoptosis was shown to occur in both the cells. 
There were fluctuations in the mitochondrial membrane 
potential ( (m)), with the activation of caspase-3/7 and 
-9 after TH treatment. TH promoted mitochondrial de-
pendent apoptosis induced by tamoxifen in both MCF-7 
and MDA-MB-231 breast cancer cell lines51. TH pro-
moted caspase oriented apoptosis in MDA-MB-231 cells. 
It reduced mitochondrion membrane potential in both cell 
lines along with tamoxifen compared to tamoxifen treat-
ment alone52. This was followed by a comparative study 
of cytotoxicity and genotoxicity of TH in combination 
with 4-hydroxytamoxifen on the breast cancer cells. Both 
the cancer cells were affected after 4-hydroxytamoxifen 
treatment, while TH treatment affected MCF-7 cells 
alone. During the combination treatment of TH and  
4-hydroxytamoxifen, TH encouraged genotoxicity of 4-
hydroxytamoxifen in cancer cells, while non-cancerous 
cells were unaffected. The selectivity of TH was evident 
from the increased expression of damaged DNA proteins 
in MCF-10A cells53. Honey’s radiation hygienization 
property in relation to anti-cancer, DNA protective and 
antimutagenicity effect was recorded by Saxena et al.54 
Honey displayed strong anti-proliferative property 
against breast cancer cell lines devoid of normal cell line 
(Int-407, intestinal epithelial cell) indicating its differen-
tial and selective cytotoxicity. The study demonstrated 
that honey provides safety during radiation treatment as 
well as maintaining its nutraceutical value54. 
 Kadir et al.55 performed in vivo experiments to evaluate 
the effect of Malaysian jungle TH on the growth of breast 
cancer in rats. About 80 mg/kg of 7,12-dimethylbenz() 
anthracene (DMBA) was used for developing breast can-
cer in rats. The growth of cancer cells was degraded by 
TH treatment at in vivo conditions. Results of the histo-
logical evaluation indicated the presence of grade 1 and 2 
tumours in the TH treated rats whereas grade 3 tumour 
was present in untreated rats. Pre-clinical study concludes 
that, differed action on DMBA-induced breast cancers 
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was exerted by TH in pre-clinical study55. Orsolić et al.56 
explored the transplantable murine mammary tumours 
when treated with honey bee products. The tumour 
growth, metastasizing ability, initiation of programmed 
cell death and necrosis in murine tumour models by  
honey bee venom royal jelly and propolis were studied. It 
was found that honey significantly subdued the tumour 
growth when orally administered (2 g/kg). They also sug-
gested that the oral or intravenous administration of  
honey bee products exerted control over metastasis56. 
Honey and its polyphenols 
Polyphenols of honey have been investigated against 
breast cancer. Phenolic phytochemicals such as apigenin, 
caffeic acid, quercetin, p-coumaric acid, eugenol, chrysin, 
kaempferol, ferulic acid, ellagic acid, hisparetin, pino-
banksin and galangin were tested against breast cancer 
cell lines. The notable effects of each phytochemical are 
discussed below. 
Apigenin 
The influence of apigenin on MCF-7 and MDA-MB-468 
breast carcinoma cells was studied by Yin et al.57 Api-
genin retarded the growth of both cancer cell lines 
through cell cycle regulatory molecules. G2/M cell cycle 
phase arrest includes reduction of cyclin B1, D1, A and 
CDK1 proteins, whereas there was no change in CDK6, 
CDK2 and cyclin E protein expression. Rb phosphoryla-
tion was degraded in MCF-7 cells by apigenin in time- 
and dose-dependent manner57. Apigenin caused degrada-
tion of HER2/neu protein and induced apoptosis in breast 
cancer cells. Furthermore cytochrome c was released 
leading to initiation of caspase-3 thereby causing cleav-
age of DFF-45. Additionally, apigenin up-regulated the 
level of p27 protein while decreasing cyclin D1, D3 and 
CDK4 in breast cancer cells58. 
 Influence over the VEGF expression by apigenin on 
MDA-MB-231 human breast cancer cells was described 
by Jin et al.59. The secretion and mRNA levels of VEGF 
as well as its transcription activity was decreased by api-
genin. Moreover apigenin treatment also initiated the ex-
pression of p53 while declining HIF-1alpha and p-AKT 
expressions in MDA-MB 231 cells. Hepatocyte growth 
factor (HGF) stimulated metastasis and the invasive 
growth was averted by apigenin in MDA-MB-231 cells60. 
Along with this, there was also a reduction in HGF-
stimulated cell-matrix adhesion and cell-endothelial cells 
adhesion in breast cancer cells after apigenin treatment. 
The anti-metastatic property also involved the blocking 
of PI3K/AKT pathway of the cancer cells. 
 Choi et al.61 combined apigenin with 5-fluorouracil and 
tested it with MDA-MB-453 breast cancer cells. The  
cellular proliferation was notably expressed by 5-
fluorouracil and apigenin combination when compared 
with the effect of 5-fluorouracil alone. The induction of 
apoptosis was due to the activation of caspase-3, ErbB2 
expression and inhibition of AKT expression40. This was 
followed by experimentation of apigenin alone with 
MDA-MB-453 cells. Apigenin induced mitochondria-
mediated apoptosis with the release of cytochrome c 
causing the activation of caspase-3 and -9 in MDA-MB-
453 cells61. Similarly, apigenin caused apoptosis of SK-
BR-3 human breast cancer cells with cell cycle arrest at 
G2/M phase along with changes in p21 (Cip1) and CDC2. 
The higher concentration of apigenin induced changes in 
Bax and cytochrome c expressions of p53 downstream62. 
Following this, apigenin was tested with MCF-7 breast 
cancer cells. Here, apigenin induced apoptosis by an  
extrinsic pathway. This involved the up-regulation of 
caspase-8 and increase in G0/G1 phase cells. Apigenin  
induced p53 and inhibited STAT3 and nuclear factor-
kappa B (NF-B) signalling in HER2 over-expressing 
MCF-7 breast cancer cells63. 
 In another study, apigenin blocked the activity of vas-
cular endothelial growth factor mRNA and protein in 
T47D human breast cancer cells treated with progestin. 
Apigenin was found to have no effect on the mRNA  
levels of progesterone and estrogen receptor- while  
obstructed the MPA-dependent secretion of VEGF64. It 
caused programmed cell death in HER2/neu-over-
expressing breast cancer cells. This was found to have a 
relationship with proteasomal degradation of HER2/neu 
via phosphatidylinositol 3-kinase/AKT-dependent path-
way. The PI3K activity was directly affected by apigenin 
while AKT kinase activity was ambiguously affected. All 
these results were apigenin-dose dependent65,66. 
 p53-dependent apoptosis was induced by apigenin in 
T47D and MDA-MB-231 breast cancer cell lines. Expo-
sure to apigenin-treated cells augmented G2/M phase, 
cleaved PARP, caspase-3 and increased p-CDC2, p21, 
Bax and p53 expression. These changes depended on  
dosage of apigenin67,68. Harrison et al.69 recorded various 
reactions induced by sub cytotoxic dose of apigenin in 
three breast cancer cell lines (MDA-MB-231, MBA-MB-
468, MCF-7 and SK-BR-3). Apigenin inhibited the pro-
liferation of MDA-MB-468 cells with production of  
excessive reactive oxygen species (ROS) and accumula-
tion of cells at G2/M phase. There was also reduction of 
phosphorylation of AKT (protein kinase B) which caused 
apoptosis of breast cancer cells69. 
Caffeic acid 
Caffeic acid phenethyl ester (CAPE), one of the deriva-
tives of caffeic acid, was tested with three breast cancer 
cell lines namely MDA-MB-231, MCF-7 and SK-BR-3 
(ref. 70). The viability of CAPE treated breast cancer 
cells was affected in a dose- and time-dependent fashion. 
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Acetylation of histone proteins with reduction of ER- 
and PR expressions was observed in MDA-231 and MCF-
7 cell lines while p-HER2 expression decreased in SK-
BR-3 cells. Alkyl esters of caffeic acid exhibited strong 
growth inhibition on MCF-7 (ref. 71). The viability of 
breast cancer cells was reduced by 80%. There was also 
inhibition of lipid peroxidation, which was concentration-
dependent. 
 Boudreau et al.72 studied the anti-cancer effect of caf-
feic acid on cancerous (MCF-7 cells) and normal (MCF-
10A cells) human mammary epithelial cell lines. Growth 
induction of MCF-7 cells decreased after caffeic acid 
treatment. This confirmed the selectivity of acid as the 
MCF-10A cells were unaffected. Effects of caffeoyl pyr-
rolidine derivative LY52 on MB-231 human breast can-
cer MDA-cells were reported by Qu et al.73 LY52 
suppressed MMP-2 activity with succinylated gelatin  
degradation. It also inhibited the invasion of MDA-MB-
231 cancer cells in mice during oral administration with 
no prominent side effects73. The compounds formed after 
oxidative dimerization of methyl caffeate affected the  
viability of MCF-7 as well as MDA-MB-231 cells. It  
induced apoptosis, which involved DNA fragmentation, 
which is one of the notable changes observed during 
apoptosis, which was again dose- and time-dependent74. 
 CAPE dose-dependent inhibited the growth of breast 
cancer stem cells by progenitor formation. Colony forma-
tion was reduced after CAPE treatment in in vitro condi-
tion. There was an upsurge in S-phase cells combined 
with reduction in G0/G1 phase cells due to caffeic acid 
treatment75. Ahn et al.76 found that the multidrug-
resistant MCF-7/Dox human breast carcinoma cells were 
affected by caffeic acid. The results obtained suggest that 
caffeic acid is potentially a chemosensitizing agent with 
greater selectivity to drug-resistant MCF-7/Dox cells  
mediated by the induction of TGF beta isotypes. Both 
TGF beta 1 and TGF beta 2 expressions were high in 
MCF-7/Dox cells after caffeic acid treatment76. 
Quercetin 
Choi et al.77 examined quercetin-induced programmed 
cell death and cell cycle arrest in human breast cancer 
cells. Quercetin treatment led to G2/M phase cell cycle  
arrest and decreased antisense p21CIP1/WAF1 expres-
sion in MCF-7 cells77. This was followed by a study on 
the antiproliferative effects of quercetin in human breast 
cancer MDA-MB-453 cells. Similar to MCF-7 cells, there 
was cell cycle arrest and induction of apoptosis in MDA-
MB-453 cells. While the expressions of Bax and PARP  
were boosted, there was degeneration of Bcl-2 expression 
and caspase-3 in cancer cells ultimately leading to  
cell death78. 
 Another study investigated effects of quercetin on cell 
viability in MDA-MB-231 cells. Quercetin affected the 
number of viable cells in a dose- and time-dependent 
manner, along with cell cycle arrest causing apoptosis. 
There was a decline in mitochondrial membrane potential 
and increase of cytosolic Ca(2+) levels. Apart from this, 
quercetin activated caspase-3, -8 and -9, along with fluc-
tuations of Bax and Bcl-2 protein levels and release of 
apoptosis-inducing factor (AIF), stimulating the translo-
cation of nucleus79. Quercetin mediated apoptosis of 
MCF-7 cells through mitochondrial pathway. The treat-
ment increased the number of S phase and sub-G1 phase 
cells in a dose- and time-dependent manner. There was a 
decrease of protein expression of CDK2, cyclins A, Bcl-2 
and B, while increasing the p53 and p57 proteins and  
activations of caspase-6, -8 and -9 in quercetin treated 
cancer cells80. 
 Soyocak et al.81 studied the effect of quercetin in rela-
tion to induction of antiproliferation and apoptosis in 
breast cancer cell lines, on Bak protein. After the treat-
ment, levels of Bak protein increased in MCF-7 cell line. 
Quercetin treatment had a dose-dependent effect on 
MCF-7 cells81. Lee and Park82 studied the anti-cancer  
activity of quercetin against MCF-7 cells. Treatment of 
quercetin caused changes in mammalian target of rapa-
mycin (mTOR), AMP-activated protein kinase (AMPK) 
and hypoxia inducible factor-1α (HIF-1), thereby con-
trolling the signalling pathways and inducing apoptosis82. 
 The combined effect of quercetin and tamoxifen in 
MCF-7 cell lines was reported. All doses of quercetin and 
tamoxifen induced apoptosis via telomerase enzyme  
activity in MCF-7 cell lines. Their synergistic effect was 
greater when compared to their individual effect41. Zhang 
et al.83 explored combinational activities of quercetin and 
quercetin-5,8-disulphonate on breast cancer cell lines. 
MCF-7 cells were found to undergo apoptosis after quer-
cetin treatment. Furthermore, quercetin’s strong antitu-
mour activity was in relation to ROS-dependent apoptosis 
pathway83. 
 Co-treatment with quercetin and 1,2,3,4,6-penta-O-
galloyl--D-glucose (5GG) motivated apoptosis in human 
breast cancer MDA-MB-231 and AU565 cells. This 
treatment reduced S-phase kinase protein 2 expression 
leading to S-phase arrest in MDA-BM-231 cells and  
reduced HER2 expression causing G2/M phase arrest in 
AU565 cells. It was concluded that quercetin enhanced 
the anti-cancer activity of 5GG in MDA-MB-231 cells42. 
Deng et al.84 described the effects of quercetin against 
MCF-7 cells in laboratory conditions. Quercetin treat-
ment led to variations in survivin mRNA expressions and 
G0/G1 phase cell cycle arrest in MCF-7 cells. All these  
effects depended on concentration and exposure time84. 
 An in vivo experiment on the synergistic effect of 
quercetin with doxorubicin injected in mice with breast 
cancer was carried out. The combination of quercetin and 
doxorubicin reduced the growth of 4T1 breast cancer 
leading to survival of mice. However, individual querce-
tin or doxorubicin treatment was not effective. Treatment 
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with quercetin also promoted lymphocyte proliferation 
and regulated Th1/Th2 cytokine imbalance85. Zhong et al.86 
examined the effects of quercetin on proliferation and 
apoptosis in transplantation tumour of breast cancer in 
nude mice. Tumour weight in mice after quercetin treat-
ment was drastically reduced. The antiproliferative action 
was due to apoptosis, which was indicated by the  
decrease in Bcl-2 protein level in the tumour cells86. 
p-coumaric acid 
Chang et al.87 studied the cytotoxic effect of p-coumaric 
acid using T-47D breast cancer cells87. There was subdual 
in the growth of cancer cells. p-coumaric acid treatment 
led to apoptosis of T-47D cells with significant accumu-
lation of cells in sub-G1 phase cells leading to G1 phase 
of cell cycle arrest. p-coumaric acid was tested on breast 
adenocarcinoma cell line. It exhibited toxicity against 
MCF-7 breast cancer cells88. This toxicity was in a dose-
dependent manner. The studies also showed that there 
were changes in calcium signal transduction and gene ex-
pression in cancer cells due to p-coumaric acid treatment. 
Eugenol 
The time- and dose-dependent effects of eugenol in  
human MCF-7 breast cancer cells were noted by Vidya 
and Niranjali89. There was a rise in the percentage of 
breast cancer cell apoptosis along with DNA fragmenta-
tion apart from depletion of intercellular glutathione  
level. The profusion of thiobarbituric acid reactive sub-
stances (TBARS) formation inferred increase in lipid 
peroxidation level89. Eugenol triggered apoptosis in 
MCF-7, T-47D and MDA-MB-231 breast cancer cells 
with down-regulation of E2F1/surviving90. Eugenol 
treatment induced different effects in different cancer 
cells at low dose. The treatment caused changes in  
NF-B and cyclin D1 genes with down regulation of 
E2F1 and upregulation of cyclin-dependent kinase inhibi-
tor p21 WAF1 protein. Similar results were seen in xeno-
graft of human breast tumours during in vivo condition. 
 Epoxypseudoisoeugenol-2-methyl butyrate (EPB), a 
eugenol derivative, was experimented with MCF-7 (es-
trogen-dependent) and BT-549 (estrogen-independent) 
breast cancer cells. There was a dose- and time-dependent 
suppression of propagation and cell cycle arrest in both 
the cell lines after EPB treatment. However, NF-B  
mediated transcription activity was seen in MCF-7 cells 
due to phorbolmyristate acetate (PMA) and tumour  
necrosis factor-7 (TNF-7). It also caused cell cycle arrest 
at G1/G0 phase in both MCF-7 and BT-549 cells. Hence, 
the anti-cancer property of EPB against both hormone-
dependent and hormone-independent breast cancer cells 
was found91. Apoptotic effect of paclitaxel in MCF-7 
cells produced by 1S-1-acetoxyeugenol acetate (AEA) 
was reported by In et al.92 which was found to be related 
to NF-B inactivation. The apoptosis induced depended 
on the dysregulation of NF-B. Phosphorylation of  
inhibitor of B-kinase complex was reduced by AEA 
treatment which led to the removal of apoptotic resis-
tance. Apart from this, the combined treatment of AEA 
and paclitaxel had a chemosensitizing role against MCF-7 
cells. 
Chrysin 
Potential effects of chrysin in MDA-MB-231 breast can-
cer cells were studied by Hong et al.93 Cell viability of 
the cells was affected depending on the dose after treat-
ment, which was accompanied by DNA fragmentation 
and mitochondrial dysfunction. Chrysin treatment  
increased expression of PPAR alpha mRNA, one of the 
early events of cell regulation, in breast cancer cells93. 
Yang et al.94 assessed the anti-metastatic activity of chry-
sin with the help of TNBC breast cancer cell lines that are 
metastatic triple-negative. Chrysin induced changes in  
E-cadherin and vimentin expression in TNBC cells. 
Moreover, AKT signal pathway played a dominant role in 
chrysin-induced anti-metastatic activity by regulating  
matrixmetalloproteinase-10 (MMP-10) and epithelial-
mesenchymal transition, suggesting chrysin as a potential 
therapeutic candidate94. 
 Both in vivo and in vitro activities of chrysin on breast 
cancer cells were recorded95. Inhibition of HDAC8 en-
zymatic activity showed that chrysin was a histone deace-
tylase inhibitor (HDACi) after enzymatic evaluation. The 
dose-dependent anti-cancer effect of chrysin against 
MDA-MB-231 cells was evident in the in vitro experi-
mentation. The xenograft model containing MDA-MB-
231 cells was orally injected with chrysin. The tumour 
size significantly decreased after 6 weeks of treatment. 
Overall, in vitro and in vivo data indicated that chrysin 
might be a standardized candidate against breast cancer. 
It suppressed the hypoxic survival and metastatic growth 
of 4T1 mouse breast cancer cells96. Growth of 4T1 cells 
in Balb/c mice was reduced by oral administration of 
chrysin. Along with this, chrysin improved the antimetas-
tatic effect of DR5 mAb. It selectively repressed hypoxia-
induced STAT3 phosphorylation avoiding HIF-1 pro-
tein along with abrogating hypoxia-induced VEGF gene 
expression. The synergistic effect (in combination with 
DR5 mAb) and individual effect of chrysin on the mouse 
model of breast cancer was also studied. 
 The activity of synthetic chrysin analogue, 5,7-
dihydroxy-8-nitrochrysin (NOC), was studied using  
human cancer cells97. The NOC treatment was not very  
effective in HBL-100 cells (ER-positive) while highly  
affecting MDA-MB-453 cells (ER-negative) and modestly 
affecting the MCF-7 cell line (ER-positive). This showed 
the selective toxicity of NOC. Moreover, NOC-induced 
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apoptosis involved a rise in reactive oxygen species 
(ROS) level and AKT dephosphorylation. Xiao et al.98 
found that NOC activated FOXO3a/Bim signalling in 
MDA-MB-453 cancer cells. Release of cytochrome c into 
cytoplasm showed that the cell death induced by NOC 
was mitochondrial pathway-dependent. Additionally, 
AKT and FOXO3a phosphorylation was suppressed by 
NOC in MDA-MB-453 cells causing apoptosis98. 
Kaempferol 
Kaempferol had effects on MCF-7 cells. The treatment of 
ER-positive breast cancer cells with kaempferol resulted 
in a time- and dose-dependent decrease in cell number. 
Kaempferol treatment reduced insulin receptor substrate 
1 (IRS-1), cyclin D1 and progesterone receptor (PR) ex-
pressions and aggregation in the nuclei. The degradation 
of ER- was also induced by kaempferol along with anti-
estrogen and estradiol99. Oh et al.100 studied kaempferol 
effect against estrogen-related diseases. Change in E2 
concentration showed the activity of kaempferol on ER-
mediated pathway in MCF-7 cell. Kaempferol treatment 
stopped the focus formation induced by E2 (ref. 100). 
 Kaempferol-3-O-rhamnoside, the bioflavonoid, also 
inhibited MCF-7 cell growth by initiation of various cas-
pase cascade pathways101. This antiproliferation happened 
in a dose-dependent pathway. Kaempferol-3-O-rhamnoside 
treatment upregulated caspase-9, -3 depending on the  
duration of treatment, and variation of poly (ADP-ribose) 
polymerase (PARP) level contributing to programmed 
cell death of the cancer cells. In another study, kaempfe-
rol was found to be the strongest inhibitor of breast can-
cer growth102. It had a concentration-oriented effect on 
MDA-MB-231 human breast carcinoma lines in in vitro 
experiment. Further, it was found to bind to the DNA and 
led to cleavage causing lysis of the cell. 
 An in-depth analysis on MCF-7 cell death was reported 
along with mechanisms103. The occurrence of apoptosis 
was specified by an increase in G1 phase cells. In addi-
tion, there was also cleavage of PARP, Bax and caspase-
7,-9 signifying the intracellular pathway of apoptosis. 
Kaempferol also down-regulated polo-like kinase 1 
(PLK-1) controlling the mitotic progression of cancer 
cells. The combined effect of quercetin and kaempferol 
was studied in MCF-7 cells. The treatment influenced the 
transcription of CYP1A1 and AhR function in a dose-
dependent manner44. CYP1A1 mRNA and CYP1A1  
enzyme activities were boosted by quercetin treatment. 
However, kaempferol treatment subdued CYP1A1  
transcription. 
 Kaempferol also abolished TCDD-induced XRE bind-
ing and caused cytotoxicity to the breast cancer cells. The 
flavonols quercetin and kaempferol, synergistically 
avoided invasion of MDA-MB-231 cells under in vitro 
condition45. They reduced matrix metallopeptidase 
(MMP-3) activity with respect to concentration changes 
along with anti-metastatic behaviour in the cancer cells. 
Margaret et al.46 reported the combined antiproliferative  
effect of quercetin and kaempferol on PMC42 human 
breast cell line. The flovonols diminished expression of 
nuclear proliferation antigen Ki67 and total protein levels 
after treatment. Thus the phenolic compounds showed 
enhanced anti-cancer activity when combined than when 
treated individually46. 
Ferulic acid 
Ferulic acid, a naturally occurring aromatic compound, 
was experimented for its phytoestrogenic effects on ER-
positive T-47D and ER-negative MDA-MB-231 cells in 
culture. The co-treatment of ferulic acid along with Ful-
vestrant had significant effect on breast cancer cells than 
ferulic acid treatment alone. Ferulic acid up-regulated 
pS2 mRNA expressions, potential marker for hormone-
dependent breast cancer and overexpression of ER-alpha 
protein in treated cancer cells104. Ferulic acid was found 
to produce synergistic effect with d-tocotrienol. There 
was high increase in G1 phase due to p21 (waf-1/cip-1) 
variation. Additionally cyclin/cyclin-dependent kinases 
(Cdks) were also affected43. Conclusively, the synergistic 
effect of d-tocotrienol and ferulic acid was predominantly 
found in cancer cells. 
Ellagic acid 
The changes in expression of human telomerase reverse 
transcriptase (hTERT)  +  + transcript after ellagic acid 
treatment were studied by Strati et al.105 using MCF-7 
(ER-positive) cancer cells. Ellagic acid increased hTERT 
 +  + mRNA expression. Meanwhile its coexistence 
with 17-estradiol significantly reduced 17-estradiol-
induced increase in hTERT  +  + mRNA. It was con-
cluded that ellagic acid exerted a chemopreventive effects 
in breast cancer by down-regulating 17-estradiol-induced 
hTERT  +  + mRNA expression. It was found to have 
antiproliferative activity on the MCF-7 breast cancer 
cells106. This antiproliferative activity was via regulation 
of the TGF-/Smad3 signalling pathway, which was due 
to decreased phosphorylation of RB proteins. Ellagic acid 
induced G0/G1 cell cycle arrest in MCF-7 cells after the 
treatment. 
 The phenolic compound also exerted anti-angiogenesis 
effects via VEGFR-2 signalling pathway in breast cancer 
cells107. The structure-based interaction between ellagic 
acid and VEGFR-2 was studied. Ellagic acid treatment 
suppressed VEGF thereby affecting angiogenesis, by  
affecting VEGFR-2 tyrosine kinase activity. Besides this, 
mitogen-activated protein kinase (MAPK) and PI3K/AKT 
pathways were also inhibited by ellagic acid. This was also 
seen in MDA-MB-231 cancer growth in the xenograft  
REVIEW ARTICLES 
 
CURRENT SCIENCE, VOL. 112, NO. 9, 10 MAY 2017 1848 
observation. Ellagic acid showed diverse effects in MDA-
MB-231 and MCF-7 human breast cancer cell lines108. In 
MDA-MB-231 cells ellagic acid had a dose-dependent 
activity along with decrease of Bcl-xL expression and  
cytochrome c release, while it had antiproliferative effect 
against MCF-7 cells. Yet, there was cell cycle arrest in 
both cell lines and decreased the expression of survivin. 
However, at high doses of ellagic acid, upregulation of  
c-fos and pS2 protein in MCF-7 cells was noted. 
 The activity of ellagic acid on MCF-7 cancer cells and 
Hs 578T lung fibroblast cells was documented under in 
vitro109. While it reduced the proliferation of MCF-7 
cells, it did not affect normal Hs 578T cells. Apoptosis 
induction was accompanied by a decrease in the levels of 
pro-matrix metalloproteinase-2 (pro-MMP-2 or gelatinase 
A), pro-matrix metalloproteinase-9 (pro-MMP-9 or  
gelatinase B) and vascular endothelial growth factor 
(VEGF165) after the treatment. Results show the selec-
tive toxicity of ellagic acid on cancer cells. Ellagic acid 
was found to have cytotoxicity in MCF-7 cancer cells 
when a zinc layered interrelation compound (EAN) was 
formed110. Cytotoxicity of EAN was determined in MCF-
7 cells and other normal cell lines. EAN displayed toxic 
effect against MCF-7 cells while reduced effect on  
normal cells. It was found that caspase-3 and -9 were  
activated, inferring the occurrence of apoptosis via mito-
chondrial pathway. In addition, EAN also increased DNA 
fragmentation, which was in a time- and concentration-
dependent manner. 
Hesperetin 
Choi recorded that hesperetin affected MCF-7 cell growth 
dose-dependently along with G1-phase cell cycle arrest111. 
Hesperetin treatment up-regulated p21Cip1 and p27Kip 
and down-regulated cyclin-dependent kinases (CDKs) 
and cyclinsin cells. In addition, the binding of CDK4 
with p21Cip1 was boosted by hesperetin, showing their 
involvement in anti-cancer activity in MCF-7 cells. Hes-
peretin impaired the uptake of insulin-generated glucose 
and inhibited proliferation in MDA-MB-231 cancer 
cells112. This was followed by inhibition of insulin-related 
redistribution of GLUT4, phosphorylation of insulin  
receptor and AKT, finally causing antiproliferation of 
breast cancer cells. 
 Lan et al.113 demonstrated hesperetin anti-proliferative 
activity in aromatase-expressing MCF-7 tumour in ova-
riectomized athymic mice113. Dietary administration of 
hesperetin significantly deterred the xenograft growth. 
There was also reduction of CDK4, Bcl-x(L), cyclin D1 
and pS2 (estrogen-responsive gene). This was followed 
by the study of prevention of letrozole-induced bone loss 
in a mouse model of breast cancer. Aromatase-over ex-
pressing MCF-7 cells were transplanted in postmeno-
pausal mice model. Hesperetin not only decreased the 
plasma estrogen level and tumour size but also reversed 
the bone volume fraction induced by letrozole114. 
Pinobanksin 
Xuan et al.115 found that pinobanksin affected MCF-7 
(ER-positive) and MDA-MB-231 (ER-negative) breast 
cancer cells in a dose- and time-dependent pattern. The 
main changes observed in the breast cancer cells were – 
increase in ANXA7 expression, excessive ROS genera-
tion and reduction of mitochondrial membrane potential. 
Apart from these, there were changes in NF-B p65  
level and p53 level. Further, apoptosis of MCF-7 and 
MDA-MB-231 cells was caused by pinobanksin treat-
ment. 
Galangin 
Tessa et al.116 reported the activity of galangin against  
the growth of human breast cancer Hs578T cell line.  
Galangin treatment induced dose-dependent apoptosis  
combined with the suppression of AhR-dependent tran-
scriptional activity in Hs578T cells. Apart from this, there 
was also G0/G1 cell cycle phase arrest and degradation of 
cyclins D3, E and A after galangin treatment leading to 
cell lysis116. Galangin affected the proliferation of human 
MCF-7 breast cancer cell line (an ER-positive). It 
blocked the cell proliferation of cancer cells. Cell death 
included binding of galangin to the estrogen receptor  
inhibition of DMBA-induced pre-B-cell apoptosis. More-
over galangin was observed to be more effective among 
the flavonoids tested117. 
Discussion and conclusion 
Cancer is a killer disease of which breast cancer is a ma-
jor threat to women around the globe claiming a second 
place. With the increase in the number of breast cancer  
patients, investigations for novel and effective anti-cancer 
agent for its prevention as well as cure are underway. 
However, there is no single drug which can cure cancer at 
all stages. In such a scenario, some scientists concentrate 
on natural diet for averting and treating this disease. One 
of the useful food substance with anti-cancer property is 
honey. Along with the crude honey, its phenolic compo-
nents are also being explored. This review summarized 
the anti-cancer activity of honey and its phenolic markers 
on breast cancer and promoted it as a promising  
candidate. 
 It is evident that both crude honey and its phenolic 
compounds are able to induce apoptosis in breast cancer 
cells. Conclusively, when the cancer cells are treated with 
honey, a range of changes like activation of caspase-3, 
caspase-8, caspase-9, boost in ROS level activating 
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Table 2. Effect of phenolic phytochemicals of honey against breast cancer 
Phytochemical tested Notable findings Reference 
   
Apigenin G2/M cell cycle phase arrest 
Decrease in cyclin B1, D1, A and CDK1 protein levels  
Induction of caspase-3 activity 
Inhibited the hepatocyte growth factor (HGF) 
Activation of ERBB2 expression 
Release of cytochrome c 
Inhibited STAT3 and NF-B signalling 
PARP cleavage  
Production of reactive oxygen species (ROS) 
50–63 
Caffeic acid phenethyl ester  
 (CAPE) 
Reduction of cell viability 
Decrease in the expression of ER- (estrogen receptor) ,PR (progesterone receptors) and p-Her2 
 (phosphorylated-HER 2) 
Inhibition of lipid peroxidation 
Inhibition of MMP-2 expression 
Decrease in G0/G1 phase cells an increase in S phase cells 
Induction of TGF beta isotypes 
64–70 
Quercetin Accumulation of cells at G2/M phase 
Increase of Bax expression  
Decrease Bcl-2 expression  
Activation of caspase-3, -8 and -9  
Increase of cytosolic Ca(2+) levels 
Promotion of apoptosis-inducing factor (AIF) release from mitochondria 
Decrease of CDK2, cyclins A protein expression 
Increase in the levels of Bak protein  
Reduced survivin protein levels  
Down-regulation of S-phase kinase protein 2 expression 
71–82 
p-coumaric acid Suppression of cell growth 
Cell cycle arrest at sub-G1 phase 
Dose-dependent toxicity 
83, 84 
Eugenol Dose- and time-dependent effect 
Induction of apoptosis 
E2f1/survivin down-regulation 
Up-regulation of cyclin-dependent kinase inhibitor p21waf1 protein 
Nf-b transcriptional activity 
Inhibited phosphorylation levels 
Enhancement of proapoptotic activity 
86–88 
Chrysin DNA fragmentation 
Mitochondrial dysfunction 
Increased expression of PPAR alpha mRNA 
Increase of E-cadherin expression  
Decrease of vimentin expression 
Inhibition of hypoxia-induced STAT3 phosphorylation 
Akt dephosphorylation 
89–94 
Kaempferol Time- and dose-dependent decrease in cancer cell number 
Up-regulation of caspase-9 and caspase-3 
Cleavage of poly (adpribose) polymerase (PARP) 
Down-regulation of polo-like kinase 1 (plk-1) 
95–99 
Quercetin and kaempferol Reduced CYP1A1 transcription 
Decrease of Matrix metallopeptidase (MMP-3) activity  
Concentration-dependent changes 
Decreased expression of nuclear proliferation antigen Ki67 
100–102 
Ferulic acid Up-regulated ps2 mRNA expressions 
Increased level of ER alpha protein expression 
G1 phase cell cycle phase arrest 
Reaction with p21 (waf-1/cip-1) 
103, 104 
(Contd) 
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Table 1. (Contd) 
Phytochemical tested Notable findings Reference 
   
Ellagic acid Down-regulation of the 17-estradiol-induced hTERT  +  + mRNA expression 
Regulation of the TGF-/Smad3 signaling pathway 
Decrease of RB protein phosphorylation 
G0/G1 phase cell cycle arrest 
Directly inhibited VEGFR-2 tyrosine kinase activity, MAPK and PI3K/Akt pathway 
Decrease of Bcl-xl expression  
Increase in the expression of cytochrome c in the cytosol  
Decrease in the levels of pro-matrix metalloproteinase-2,9 
DNA fragmentation 
105–110 
Hesperetin Down-regulation of cyclin-dependent kinases (cdks) and cyclins  
Up-regulation of p21Cip1 and p27Kip1 
Inhibition of insulin-induced redistribution of GLUT4 
Decrease in the expression of the estrogen-responsive gene ps2 
Reduction in the plasma estrogen level 
111–114 
Pinobanksin Dose- and time-dependent cytotoxic effect 
Drastic increase of ANXA7 expression and ROS level and NF-B p65 level 
Change in p53 level 
115 
Galangin Suppression of Ahr-dependent transcriptional activity 
Cell cycle block at G0/G1 phase  
Down-regulation of cyclins D3, E and A 
Inhibits DMBA-induced pre-B-cell apoptosis 
116, 117 
 
 
 
Figure 4. Targets of honey and its phenolic markers against breast cancer cells. 
 
 
mitochondrial pathway, lipid layer breakage, increase of 
G1/G2/M phase cells, up-regulation of Bax regulators, 
down-regulation of Bcl-2 proteins and p53 pathway 
which cause the DNA fragmentation and down-regulation 
of apoptosis dependent genes like CDK 1 and TP53, may 
occur (Figure 4). Table 2 shows the major observations 
against breast cancer by phenolic phytochemicals. 
 Polyphenols like caffeic acid64–70, chrysin87–91, querce-
tin, kaempferol98–102 and ellagic acid106 are found to 
down-regulate the matrix metallopeptidase in diverse 
breast cancer cells like MCF-7 and MDA-MB-231.  
Matrix metallopeptidases (MMP) is an enzyme that  
belong to zinc-metalloproteinases family and tangled in 
the degradation of extracellular matrix during physiological 
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procedures, such as, development of the embryo, wound 
healing, cell migration, angiogenesis, etc. MMPs expres-
sions are high in cancer cells and they have an alleged 
role in extracellular matrix remodelling and angiogenesis 
and are also considered as possible mediators of invasion 
and metastasis115. MMP is said to be one of the important 
biomarkers of breast cancer since MMPs 1, 2, 7-11, 13, 
14 and 16 expressions were predominantly found in 
MDA-MB-231, T47D and MCF-7 cancer cell lines116. In 
another study, MMP-9 was concluded to be the gene ex-
pression signature of different grades (G1, G2 and G3) of 
invasive ductal carcinoma of breast cancer. Higher ex-
pression of MMPs was associated with higher grades of 
tumour invasion and metastasis in breast cancer. Hence, 
from the above studies, it may be suggested that honey 
and its phytochemicals are able to inhibit MMPs, one of 
the recognized biomarkers of breast cancer, suppressing 
its invasion and metastasis. 
 Thus honey and its phenolics can be used to prevent as 
well as treat breast cancer. However, there are some limi-
tations associated with this. Phenolic composition of  
honey around the world is different depending on the nec-
tar source, geographical origin and processing conditions. 
Nevertheless, success of honey against cancer depends on 
its bioactive components, which in turn offer diverse 
challenges for honey producers. Apart from this, there are 
some other gaps that needed to be fulfilled. From this  
review, it is evident that there have been lot of investiga-
tions done on the anti-cancer property of honey as well as 
phenolics in some breast cancer cell lines and animal 
models. However, more information regarding the genetic 
response would be helpful. This may be illustrated by in 
vivo studies on knock-out mouse model. In addition,  
human clinical trials regarding effect of honey and its 
phenolic components should be performed. For this, both 
healthy volunteers and participants with increased risk for 
breast cancer are to be recruited in large groups which 
demands more investments. Hence it is high time for  
researchers and other key-players to develop a sound 
clinical knowledge about honey and its components in 
order to spearhead the campaign against breast cancer. 
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